Background: Low-density lipoprotein receptor-related protein 1 (LRP-1) is a scavenger receptor that regulates adaptive immunity and inflammation. LRP-1 is not known to modulate the pathogenesis of allergic asthma. Objective: We sought to assess whether LRP-1 expression by dendritic cells (DCs) modulates adaptive immune responses in patients with house dust mite (HDM)-induced airways disease.
In addition to its canonical role in endocytosis, LRP-1 also participates in the regulation of inflammation and adaptive immune responses. [13] [14] [15] For example, macrophage-specific deletion of LRP-1 decreases VLDL uptake and thereby promotes atherogenesis in hypercholesterolemic mice by increasing matrix metalloproteinase 9 activity and production of proinflammatory mediators, such as TNF-a and CCL2 (monocyte chemoattractant protein 1). 13 Lrp1 2/2 mice display a phenotype of enhanced ligand-specific inflammatory responses that are regulated by nuclear factor kB (NF-kB) and miR-155 in macrophages. 7 Furthermore, the mechanism by which LRP-1 suppresses NF-kB signaling might involve downregulation of signaling by TNF receptor 1. 16 Consistent with an anti-inflammatory function in macrophages, LRP-1 has been demonstrated to promote an M2 phenotype. 17 LRP-1 has also been shown recently to attenuate neuroinflammation and microglial immune responses by suppressing signaling through the c-Jun N-terminal kinase and NF-kB pathways. 18 LRP-1 modulates host defense and antitumor immune responses by facilitating antigen uptake and presentation. For example, an important function of LRP-1 is the binding, internalization, and clearance of apoptotic cells through formation of a multimeric protein complex comprising the scaffolding protein, RAN-binding protein 9, and the receptor tyrosine kinase, AXL. 19 This multimeric protein complex facilitates efferocytosis by DCs and the subsequent cross-presentation of viral antigens expressed by apoptotic cells to CD8 1 T cells, which promotes host defense against viral infections. Similarly, binding of bacterial or tumor cell-derived heat shock proteins (HSPs) to LRP-1, which is also known as CD91, facilitates the high-efficiency uptake of exogenous antigenic peptides by antigen-presenting cells for chaperone-based presentation that primes effector CD4
1 and [20] [21] [22] Interestingly, LRP-1 also modulates proinflammatory cytokine production and initiation of inflammatory responses in LPSinduced acute lung injury through a calreticulin axis that binds surfactant proteins A and D to activate downstream p38 and NF-kB signaling pathways. 23 Previously, we identified an endogenous apolipoprotein E-LDL receptor pathway in the lung that regulates airway hyperreactivity and mucous cell metaplasia in house dust mite (HDM)-induced allergic asthma. 24 Moreover, we demonstrated that the VLDL receptor on DCs acts as a negative regulator and thereby attenuates HDM-induced airway inflammation and adaptive immune responses. 25 Here we hypothesized that another LDL receptor family member, LRP-1, might similarly regulate DC function and thereby modify adaptive immune responses to HDM, which is a common and clinically relevant aeroallergen. We show that the cell-specific deletion of LRP-1 on CD11c 1 cells enhances HDM-induced allergic sensitization, adaptive T H 2 immune responses, and eosinophilic airway inflammation through a mechanism that involves increased antigen uptake and presentation by DCs. In addition, we demonstrate that circulating myeloid dendritic cell (MDC) subsets from human subjects with eosinophilic asthma have decreased LRP-1 expression compared with healthy nonasthmatic subjects. We also show that LRP-1 expression by circulating MDC subsets is negatively correlated with peripheral blood eosinophil counts in asthmatic patients, which suggests a possible role for LRP-1 in modulating adaptive immune responses in human subjects. Therefore, we propose that LRP-1 functions as a negative regulator of DC-mediated adaptive immune responses in HDM-induced allergic eosinophilic airway inflammation.
METHODS

Quantification of LRP-1 expression on peripheral blood DCs
Informed consent was obtained from 38 subjects who participated in protocol 99-H-0076, which was approved by the Institutional Review Board of the National Heart, Lung, and Blood Institute (NHLBI). All asthmatic patients had evidence of either a positive response to an inhaled b 2 -agonist or a positive methacholine bronchoprovocation challenge test result, whereas all healthy nonasthmatic subjects had a negative methacholine bronchoprovocation challenge test result. The presence or absence of allergy was determined based on results of skin testing, which was performed either at the NHLBI or by their local physician, or patient history. Allergy skin testing at the NHLBI was performed with a Multi-Test II applicator, which was a generous gift from Lincoln Diagnostics (Decatur, Ill), with glycerin as a negative control and histamine as a positive control (Hollister-Stier, Spokane, Wash). Allergy was defined by the presence of skin test reactivity to at least one of 6 common aeroallergens, which included HDM (Dermatophagoides farinae), cockroach (Periplaneta americana and Battella germanica), cat hair, Aspergillus fumigatus, ragweed (giant and short), and grasses (Kentucky Bluegrass, Orchard Redtop, Timothy sweet vernal grass, meadow fescue, and perennial ryegrass).
Peripheral blood was collected in 10-mL sodium heparinized Vacutainers (Becton Dickinson, Franklin Lakes, NJ), and red blood cells (RBCs) were lysed with ACK lysing buffer. Peripheral blood cells were reacted with the following antibodies for flow cytometry: anti-human CD11c-BV785 (clone 3.9), anti-human CD1c-phycoerythrin (PE)/Dazzle 594 (clone L161), anti-human CD141-PE-Cy7 (clone M80), anti-human CD16-peridinin chlorophyll protein (PerCP)/Cy5.5 (clone 3G8), anti-human CD123-BV650 (clone 6H6), anti-human HLA-DR-allophycocyanin (APC) Cy7 (clone W6/32), and anti-human Lin 1-fluorescein isothiocyanate, all from BioLegend (San Diego, Calif), and Alexa Fluor (AF) 647-conjugated rabbit mAb to LRP-1 (ab92544) from Abcam (Cambridge, United Kingdom). Cells were incubated for 15 minutes with human Fcg receptor-binding inhibitor (Thermo Fisher Scientific, Waltham, Mass), reacted with antibodies, and washed with PBS. The fixable viability dye was then added, followed by fixation and permeabilization.
Cellular debris and doublets were excluded by using physical scatter properties of RBC-lysed whole blood cells, and dead cells were excluded by using fixable live-dead exclusion dye. Type 1 myeloid dendritic cells (MDC1s) were identified as viable/Lin-1 2 cells expressing CD11c ) were adoptively transferred in 20 mL of PBS through intranasal administration on day 0 to recipient naive C57BL6 wild-type (WT) mice. All recipient mice received daily intranasal HDM challenges (50 mg) on days 9, 11, 13, and 15, and end points were analyzed on day 15. Two independent experiments were performed for each model.
Bronchoalveolar lavage and lung histopathology
Bronchoalveolar lavage (BAL) was performed 3 times with 0.5 mL of PBS, and red blood cells were lysed with ACK buffer for 2 minutes at 48C, as previously described. 27 Bronchoalveolar lavage fluid (BALF) cells were resuspended in 0.3 mL of RPMI 1640 containing 10% FBS, and cell counts were performed with a hemocytometer, whereas differential cell counts were performed on Diff-Quik-stained cytospin slides (Siemens, Deerfield, Ill). Lungs were inflated with 10% formalin to a pressure of 25 Levels of HDM-specific serum IgE and IgG 1 were quantified, as previously described. 27 Ninety-six-well plates were coated overnight with 0.01% HDM in PBS and blocked with 1% BSA in PBS. Serum samples were added to the plates for 1 hour and washed 6 times with PBS with 0.05% Tween 20 before incubation with biotinylated anti-mouse IgE or IgG 1 (PharMingen, San Jose, Calif) for 1 hour. Plates were washed 6 additional times, streptavidin-horseradish peroxidase (R&D Systems, Minneapolis, Minn) was added for 30 minutes, and the amount of bound HDM-specific antibody was determined by the addition of TMB substrate.
Measurement of airway hyperresponsiveness
Mice were anesthetized, and airway resistance to different doses of methacholine was measured with an Elan RC Fine Pointe system (Buxco, Wilmington, NC), as previously described. 24 Mice were mechanically ventilated after tracheal cannulation with a 19-gauge beveled metal catheter, with a constant inspiratory flow before nebulization with increasing doses of methacholine (0-10 mg/mL). Airway resistance was recorded at 10-second interval for 3 minutes, and average values are represented as centimeters of H 2 O per milliliter per second.
HDM restimulation of mediastinal lymph node cells
Single-cell suspensions from both the right and left mediastinal lymph nodes (MLNs) of mice were generated. MLN cells (0.2 3 10 6 /mL) were cultured in round-bottom 96-well plates and restimulated with HDM (100 mg/mL) for 72 hours at 378C in RPMI medium with 10% FBS. Concentrations of IL-4, IL-5, IL-13, or IFN-g in supernatants were measured by using sandwich ELISA kits, with limits of sensitivity of 15.6 pg/mL for IL-4, 31.25 pg/mL for IL-5 and IFN-g, and 62.5 pg/mL for IL-13 (R&D Systems).
Lung DC migration assay
HDM was labeled with the AF647 protein labeling kit (Invitrogen), according to the manufacturer's instructions. Mice received intratracheal administration of AF647-HDM (50 mg per administration of sensitization) dissolved in 80 mL of PBS by using a 24-gauge sterile polyurethane catheter connected to the outlet of a micropipette, as previously described. 27 At 72 hours after injection, migrating DCs were quantified in digested lungs, and MLNs were quantified by using flow cytometry as
Flow cytometry
Lung cells were isolated by means of enzymatic digestion with Liberase (100 mg/mL; Roche, Indianapolis, Ind) and DNase I (0.2 mg/mL; DN25; Sigma, St Louis, Mo; total volume, 1-2 mL per lung) and incubated at 378C for 25 minutes with agitation. Cells from digested lungs were incubated with Fc Block (BD Biosciences, San Jose, Calif) to react with Fcg III/II receptors before surface staining. Mouse DC subsets were identified and characterized by using anti-mouse Siglec-F-PE-CF594, CD11c-APC-Cy7, MHCII-PECy7, CD11b-PerCP-Cy5.5, CD103-APC, PDCA1-AF488, Mar-1-eFluor450, CD64-PE, Toll-like receptor (TLR)-4-APC, Dectin-1-PE, CD205-PerCPCy5.5, and CD206-BV785 antibodies, all from BioLegend (San Diego, Calif); CD80-PE-Cy5, CD86-605NC, and dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin (DC-SIGN)-eFluor660, all from Thermo Fisher Scientific (Waltham, Mass); Dectin-2-AF647 from Bio-Rad Laboratories (Hercules, Calif); and TLR5-PE from Novus (Littleton, Colo). CD4 1 regulatory T (Treg) cells were identified by using APC-conjugated anti-CD3, BV650-conjugated anti-CD4, and PE-Cy7-conjugated anti-CD25, all from Thermo Fisher Scientific. For intracellular forkhead box protein 3 (Foxp3) staining, cells were fixed and permeabilized with Foxp3 staining buffer (Thermo Fisher Scientific) and then reacted with a PE-conjugated anti-mouse Foxp3 antibody (0.5 mg per 10 6 cells; Clone NRRF-30; Thermo Fisher Scientific). Data were acquired on an LSRII (BD Biosciences) equipped with 407, 488, 532, and 633 LASER lines by using DIVA 8 software and analyzed with the FlowJo software (version 9.9.5; TreeStar, San Carlos, Calif). Cellular debris was excluded by using a forward light-scatter/side-scatter plot.
OT-II coculture
The ability of DCs to induce ex vivo antigen-specific T-cell proliferation was assessed by using carboxyfluorescein succinimidyl ester (CFSE)-labeled splenic CD4 T cells from naive DO11.10 T-cell receptor (TCR; C.Cg-Tg [DO11.10]10Dlo/J) transgenic mice (Jackson Laboratories, Bar Harbor, Me), which express a transgenic MHCII-restricted TCR that recognizes the ovalbumin (OVA) peptide antigen. 27 BMDCs from 
Statistics
Data were analyzed with GraphPad Prism software (version 7.0b; GraphPad Software, La Jolla, Calif), with either an unpaired t test for normally distributed data or a Mann-Whitney test for nonnormally distributed data. Multiple comparisons were analyzed by using 1-way ANOVA with a Sidak multiple comparison test or 2-way ANOVA. Correlation analyses between LRP-1 expression and peripheral blood eosinophil counts were performed by using Spearman correlation. Data are presented as means 6 SEMs. A P value of less than .05 was considered significant.
RESULTS
LRP-1 expression is decreased on peripheral blood MDCs from patients with eosinophilic asthma
Increased numbers of peripheral blood eosinophils are a biomarker of type 2-high asthma. [29] [30] [31] [32] Here, we hypothesized that LRP-1 expression by peripheral blood DCs might be modified in asthmatic patients with high peripheral blood eosinophil counts (>260 cells/mL) compared with that in asthmatic patients with low peripheral blood eosinophil counts (<260 cells/mL) or healthy nonasthmatic subjects who also had low peripheral blood eosinophil counts (<260 cells/mL; Fig 1,  A) . [33] [34] [35] Demographic information regarding the high-and low-eosinophil groups are presented in Table E1 Fig 1, B , LRP-1 expression by the MDC1, MDC2, and CD16 1 MDC subsets was decreased significantly in the eosinophil-high asthmatic group compared with the healthy nonasthmatic group, whereas there was no difference between the groups regarding LRP-1 expression by pDCs. Furthermore, when all eosinophil-high and eosinophil-low asthmatic patients were combined into a single cohort, there were significant negative correlations between peripheral blood eosinophil counts and LRP-1 expression by the MDC1 (Spearman r 5 20.46, P 5 .019), MDC2 (Spearman r 5 20.51, P 5 .008), and CD16
1 MDC (Spearman r 5 20.39, P 5 .047) subsets, whereas there was a trend for a negative correlation among pDCs (Spearman r 5 20.37, P 5 .06). Collectively, these results show that MDC subsets from patients with eosinophil-high asthma have lower levels of LRP-1 expression than those from healthy nonasthmatic subjects and that a negative correlation exists between LRP-1 expression by MDC subsets and peripheral blood eosinophil counts in asthmatic patients.
Next, we used a murine model to assess whether sensitization and challenge with HDM modifies the cell-surface expression of LRP-1 on CD11c 
CD64
1 monocyte-derived dendritic cells (moDCs) in the lungs of saline-challenged mice. 36 Furthermore, after sensitization and challenge with HDM, the percentage of both LRP-1 1 cDCs and moDCs in the lung were significantly reduced. ; CD11c-Cre mice were sensitized by means of intraperitoneal injection of HDM plus aluminum hydroxide, followed by multiple intranasal HDM challenges (Fig 2, A) . As shown in Fig 2, B , the total number of BALF inflammatory cells recovered from HDM-challenged Lrp1 fl/fl ; CD11c-Cre mice were significantly increased compared with those from control Lrp1 fl/fl mice, which represented increases in eosinophil, alveolar macrophage, and lymphocyte counts. Similarly, lung histopathology showed an increase in the extent of peribronchial inflammatory cell infiltrates (Fig 2, C) and mucous cell metaplasia (Fig 2, C and D) in HDM-challenged Lrp1 fl/fl ; CD11c-Cre mice compared with Lrp1 fl/fl mice. In contrast, there was no significant difference in airway hyperresponsiveness (AHR) between HDM-exposed Lrp1 fl/fl ; CD11c-Cre and Lrp1 fl/fl mice (Fig 3, A) . Restimulation of MLN cells from Lrp1 fl/fl ; CD11c-Cre mice with HDM showed significant increases in the production of the T H 2 cytokines IL-4, IL-5, and IL-13, whereas there was no change in production of IFN-g (Fig 3, B) . mice compared with Lrp1 fl/fl mice (Fig 3, C) . Lastly, HDM-challenged Lrp1 fl/fl ; CD11c-Cre mice had increases in HDM-specific serum IgE and IgG 1 levels (Fig 3, D) compared with those in Lrp1 fl/fl mice, which is indicative of augmented allergic sensitization. Collectively, these data demonstrate that HDM-challenged Lrp1 fl/fl ; CD11c-Cre mice have a phenotype of increased allergic sensitization, T H 2-mediated adaptive immune responses, mucous cell metaplasia, and eosinophilic airway inflammation in response to HDM that was associated with a reduction in lung Treg cell numbers.
To confirm that the phenotype in HDM-challenged Lrp1 fl/fl ; CD11c-Cre mice of augmented eosinophilic inflammation in the absence of modified AHR was not related specifically to the use of aluminum hydroxide as an adjuvant during the sensitization phase, we assessed whether similar results would be obtained if mice were sensitized and challenged by means of intranasal administration of HDM (25 mg) alone on a daily basis 5 days per week for 5 weeks (see Fig E3, ; CD11c-Cre mice that had been sensitized and challenged with HDM alone were significantly increased compared with those in control Lrp1 fl/fl mice, which again represented increases in eosinophil, alveolar macrophage, and lymphocyte counts (see Fig E3, B) . Again, there was no significant difference in AHR between HDM-challenged Lrp1 fl/fl ; CD11c-Cre and Lrp1 fl/fl mice (see Fig E3, C) , whereas flow cytometry demonstrated that there was a significant reduction in the number of CD3 ; CD11c-Cre mice compared with Lrp1 fl/fl mice (see Fig E3, D) . BALF levels of CCL24 were also increased significantly in HDM-challenged Lrp1 fl/fl ; CD11c-Cre mice compared with Lrp1 fl/fl mice (see Fig E3, E) . Thus a similar phenotype of enhanced eosinophilic airway inflammation that was dissociated from airway hyperreactivity was present when ; CD11c-Cre mice increases HDM-mediated eosinophilic airway inflammation. A, BMDCs from Lrp1 fl/fl ; CD11c-Cre and Lrp1 fl/fl donor mice were pulsed ex vivo with saline or HDM (100 mg$mL 21 ) for 16 hours. CD11c 1 CD11b 1 MHCII hi DCs (2.5 3 10 4 ) were adoptively transferred to WT C57BL6 recipient mice by means of intranasal administration on day 0, and intranasal HDM challenges (50 mg) were administered on alternate days, from day 9 through day 15, to all recipient mice before end point analysis on day 16. B, Number of total BALF inflammatory cells and inflammatory cell subtypes in recipient WT mice (n 5 6-10 mice per group). *P < .05, HDM-pulsed Lrp1 fl/fl mice were pulsed with HDM or saline and transferred adoptively to naive WT mice that subsequently received multiple intranasal HDM challenges to induce allergic airway inflammation (Fig 4, A) . As shown in Fig 4, B, the number of total BALF inflammatory cells, which were specifically composed of eosinophils and alveolar macrophages, were significantly increased in WT recipients of CD11b 1 DCs from Lrp1 fl/fl ; CD11c-Cre donor mice compared with WT recipients of CD11b
1 DCs from Lrp1 fl/fl donor mice. Similarly, lung histology showed increases in peribronchial inflammatory cell infiltrates (Fig 4, C) and mucous cell metaplasia (Fig 4, D (Fig 4, E) and BALF levels of the C-C chemokine CCL24 (Fig 4, F) were also significantly increased in the WT recipients of Next, we considered whether specific deletion of LRP-1 in CD11c 1 cells would modify the number of lung DC subsets or the surface expression of costimulatory molecules in response to HDM challenge in mice that had been sensitized with HDM plus aluminum hydroxide. As shown in Fig 5, A, there were no significant differences in numbers of total lung CD11c (Fig 5, B) . Therefore, the phenotype of enhanced eosinophilic airway inflammation in HDM-challenged Lrp1 fl/fl ; CD11c-Cre mice was not mediated by changes in the number of DC subsets in the lung. Similarly, there were no differences in the numbers of cDCs, moDCs, CD103
1 DCs, and pDCs in the lungs of Lrp1 fl/fl ; CD11c-Cre and Lrp1 fl/fl mice that had been sensitized and challenged by administration of intranasal HDM without adjuvant (see Fig E4 in ; CD11c-Cre mice. We found that cell-surface expression of the costimulatory molecule CD86 was increased on CD11b
1 DCs from the lungs of HDM-challenged Lrp1 fl/fl ; CD11c-Cre mice, whereas there was no difference in CD80 expression (Fig 5, C) . We also considered whether cell-surface expression of C-type lectin receptors (CLRs) and TLRs by CD11b 1 lung DCs might be modified in Lrp1 fl/fl ; CD11c-Cre mice as a possible mechanism by which allergic inflammation is augmented. [38] [39] [40] [41] As shown in 
LRP-1-deficient DCs have increased antigen uptake and presentation
We next hypothesized that antigen uptake and presentation functions of LRP-1-deficient DCs might be enhanced as a mechanism by which HDM-induced eosinophilic airway inflammation is augmented in Lrp1 fl/fl ; CD11c-Cre mice. AF647-labeled HDM was administered to the lungs of Lrp1 fl/fl ; CD11c-Cre and Lrp1 fl/fl mice, and antigen uptake was assessed by using flow cytometry. As shown in Fig 6, A, there was a significant increase in HDM uptake by CD11b 1 lung DCs from Lrp1 fl/fl ; CD11c-Cre mice compared with Lrp1 fl/fl mice (14.28% 6 2.6% vs 2.46% 6 0.31%), whereas there was no difference in uptake of HDM antigen by lung CD11b 2 DCs. In addition, there was no difference in the frequency of AF647-HDM 1 CD11b 1 or CD11b 2 DCs from Lrp1 fl/fl ; CD11c-Cre and Lrp1 fl/fl mice that migrated to MLNs after uptake of HDM antigen in the lung (Fig 6, B) . Collectively, these experiments show that lung DCs from Lrp1 fl/fl ; CD11c-Cre mice have an enhanced antigen uptake capability, whereas subsequent migration to MLNs was not modified.
Next, CD11c ; CD11c-Cre mice mediate significant increases in both T-cell proliferation (Fig 6, C) and T H 2 cytokine production (Fig 6, D) compared with CD11c
1 BMDCs from Lrp1 fl/fl mice after ex vivo stimulation with the OVA 323-339 peptide. Collectively, these experiments show that LRP-1-deficient CD11c
1 DCs have an enhanced ability to present antigen to CD4
1 T cells and thereby induce effector T H 2 inflammatory responses.
DISCUSSION
CD11b
1 cDCs play key roles in initiating T H 2 cell differentiation and effector cytokine production, which mediate allergic airway inflammation. [42] [43] [44] Previously, we have shown that the VLDL receptor functions as a negative regulator of DC function in experimental HDM-induced asthma. However, limited data exist regarding the function of another LDL receptor family member, LRP-1, in mediating the ability of DCs to induce allergen-mediated adaptive immune responses in asthma. 21, [45] [46] [47] For example, LRP1 polymorphisms have been associated with food allergen sensitization in asthmatic children who participated in the Mexico City Childhood Asthma Study. 48 In other settings, LRP-1 expression by DCs has been shown to mediate antigenspecific immune responses. LRP-1 on DCs can facilitate the receptor-mediated uptake of a wide variety of antigens, including soluble tetanus toxin C fragment or activated a 2 -macroglobulintetanus toxin C fragment complexes, which elicit T-cell proliferation and enhance primary antigen-specific immune responses. 45, 49, 50 Furthermore, LRP-1 has been shown to bind and internalize immunogenic HSPs, such as HSP70, HSP90, gp96, and calreticulin, 22, 46, 51 which are processed and presented by MHC class I or MHCII molecules to provide the appropriate 1 Siglec-F 2 MHCII hi total lung DCs (Fig 5, A) and percentage of lung moDC, myeloid cDC, CD103
1 DC, and pDC subsets (Fig 5, B) , as quantified by using flow cytometry ; CD11c-Cre mice versus Lrp1 fl/fl mice (n 5 4-9 mice per group). *P < .05, unpaired t test.
J ALLERGY CLIN IMMUNOL VOLUME 142, NUMBER 4 signal for T-cell priming. 21 LRP-1 also mediates DC responses in the setting of host defense against viral infections and in patients with cancer. 19, 51, 52 Peripheral blood eosinophil counts can be used as a biomarker to identify patients with eosinophilic asthma and are also correlated with asthma severity. 29, 53, 54 Here, we show that patients with eosinophil-high asthma have decreased LRP-1 expression on circulating MDC1, MDC2, and CD16 DCs, but not CD14 1 monocytes, are the primary antigenpresenting cells in circulating blood that facilitate receptormediated antigen uptake and presentation. 45 This is clinically relevant because these DC subsets also express the high-affinity (Fig 6, A) and MLNs (Fig 6, B) IgE receptor (FcεRI), which contributes to the pathogenesis of allergic asthma. 55 Similarly, we show that HDM suppresses LRP-1 expression by CD11b 1 cDCs and moDCs in the murine lung. This is consistent with prior reports demonstrating downregulation of cell-surface LRP-1 expression on myeloid cells in response to bacterial LPS and cigarette smoke. 56, 57 Collectively, these findings support the possibility that reduced LRP-1 expression by circulating MDCs in patients with eosinophilic asthma, as well as by CD11b 1 cDCs and moDCs lung DCs from HDM-challenged mice, modify the severity of eosinophilic asthma.
We used 2 murine models to investigate whether LRP-1 expression by DCs modulates the pathogenesis of allergic sensitization to HDM and the subsequent induction of eosinophilic airway inflammation and T H 2 adaptive immune responses in the lung. First, we created a mouse with a specific deletion of LRP-1 in CD11c
1 cells, such as DCs and alveolar macrophages, to characterize the role of LRP-1 expression in HDM-induced airways disease. We show that HDM-challenged Lrp1 fl/fl ; CD11c-Cre mice display a phenotype of augmented allergic sensitization and enhanced T H 2 immune responses to HDM that were associated with increased eosinophilic airway inflammation and mucous cell metaplasia. HDM restimulation of draining MLN cells from Lrp1 fl/fl ; CD11c-Cre mice showed increased production of the T H 2 cytokines IL-4, IL-5, and IL-13, which are key regulators of eosinophilic airway inflammation and mucous cell metaplasia. [58] [59] [60] Furthermore, there was a reduction in numbers of CD4 ; CD11c-Cre mice also had increased expression of TLR5, which promotes allergic sensitization to flagellin-containing aeroallergens. ; CD11c-Cre mice that were sensitized with HDM plus adjuvant (ie, aluminum hydroxide) was not associated with concomitant modifications in AHR. This finding was confirmed when HDM alone was used for both allergic sensitization and challenge, which shows that the dissociation between AHR and eosinophilic airway inflammation was not merely a consequence of a sensitization model that used aluminum hydroxide as an adjuvant. A dissociation between eosinophilic airway inflammation and AHR has been reported previously both in murine models and human studies, which suggests that distinct pathogenic pathways can regulate the development of these cardinal manifestations of asthma. [66] [67] [68] [69] [70] [71] [72] Consistent with this concept, our results suggest that LRP-1 regulates HDM-induced eosinophilic airway inflammation, but not AHR, in Lrp1 fl/fl ; CD11c-Cre mice. CD11b 1 cDCs that reside in the airway continuously sample the local environment and take up inhaled aeroallergens, such as HDM, after which they migrate to nearby draining lymph nodes to present antigens to T cells. 73 As such, CD11b 1 cDCs are the major lung DC subset that mediates the priming and activation of CD4 1 effector T cells in allergen-mediated airway inflammation. 27, 74, 75 Furthermore, after sensitization and challenge with HDM, migratory CD11b 1 cDCs have been identified as the primary DC subset that induces T H 2 immune responses in lymph nodes, whereas the function of CD11b 1 moDCs is to produce proinflammatory cytokines and facilitate allergen presentation and allergen-mediated eosinophilic inflammation in the lung. 36 Here we show that adoptive transfer of HDM-pulsed CD11b
1 DCs from Lrp1 fl/fl ; CD11c-Cre mice has an increased ability to induce allergic sensitization, as indicated by increased serum levels of HDM-specific IgE and IgG 1 , as well as eosinophilic airway inflammation. In addition, BALF levels of the C-C chemokine CCL24 (eotaxin-2), which has chemotactic activity toward eosinophils, were increased. 76 Collectively, these results confirm the conclusion that the phenotype of increased allergic sensitization and eosinophilic airway inflammation that we observed in HDM-challenged Lrp1 fl/fl ; CD11c-Cre mice was mediated specifically by CD11b 1 DCs. Uptake of HDM antigen in the lung is almost exclusively mediated by the CD11b 1 DC subset, whereas CD11b 2 DCs can also mediate HDM uptake at high doses. 36, 38 After antigen uptake in the lung, DCs are transported to draining MLNs through a CCR7-dependent process, where they induce expansion of naive T cells to mount a T H 2 immune response. 77 By subdividing the lung and MLN DC populations, we show that CD11b
1 DCs from the lungs of naive Lrp1 fl/fl ; CD11c-Cre mice have an increased ability to take up HDM antigen, whereas there was no difference in migration of HDM 1 CD11b 1 DCs to the draining MLNs. In addition, we show that OVA peptide-pulsed CD11c ; CD11c-Cre mice.
In conclusion, the present study demonstrates, for what we believe is the first time, a role for LRP-1 in modulating DC function in the pathogenesis of T H 2 immune responses to HDM in experimental allergen-induced asthma. Our data are consistent with the conclusion that LRP-1 functions as a negative regulator of CD11bthe LDL receptor family member, LRP-1, as a negative regulator of DC function during the pathogenesis of allergic asthma. 
